Predicting systemic disease in patients with esophageal cancer after esophagectomy a multinational study on the significance of the number of involved lymph nodes

Annals of Surgery

Volumn 248, Issue 6, 2008, Pages 979-984

  Peyre, Christian G ^a   Hagen, Jeffrey A ^a   DeMeester, Steven R ^a   Van Lanschot, Jan J B ^b   Hölscher, Arnulf ^c   Law, Simon ^d   Ruol, Alberto ^e   Ancona, Ermanno ^e   Griffin, S Michael ^f   Altorki, Nasser K ^g   Rice, Thomas W ^a   Wong, John ^d   Lerut, Toni ^c   DeMeester, Tom R ^a,h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF PADOVA   (Italy)

^f Northern Oesophagogastric Cancer Unit   (United Kingdom)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h 1510 San Pablo St ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ASIA; CANCER PATIENT; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS SQUAMOUS CARCINOMA; EUROPE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; POPULATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; RISK; SYSTEMIC DISEASE; UNITED STATES; UNIVARIATE ANALYSIS; ADENOCARCINOMA; AGED; CANCER INVASION; CLINICAL TRIAL; ESOPHAGUS TUMOR; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES;

EID: 58149399165     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181904f3c     Document Type: Article

References (26)

1. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N EnglJMed. 1997;337:161-167.
2. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
3. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335:462-467.
4. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41:391-393.
5. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 2003;21:4592-4596.
6. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. JThorac Cardiovasc Surg. 1997;114:205-209.
7. Armanios M, Xu R, Forastiere AA, et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22:4495-4499.
8. Pouliquen X, Levard H, Hay JM, et al. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg. 1996;223:127-133.
9. Rice TW, Mason DP, Murthy SC, et al. T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg. 2007;133:317-324.
10. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530.
11. Ellis FH Jr, Watkins E Jr, Krasna MJ, et al. Staging of carcinoma of the esophagus and cardia: a comparison of different staging criteria. J Surg Oncol. 1993;52:231-235.
12. Skinner DB, Little AG, Ferguson MK, et al. Selection of operation for esophageal cancer based on staging. Ann Surg. 1986;204:391-401.
13. Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132:1374-1381.
14. Barbour AP, Rizk NP, Gonen M, et al. Lymphadenectomy for adeno- carcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol. 2007;14:306-316.
15. Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239 -1246.
16. Dutkowski P, Hommel G, Bottger T, et al. How many lymph nodes are needed for an accurate pN classification in esophageal cancer? Evidence for a new threshold value. Hepatogastroenterology. 2002;49:176-180.
17. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003;125:1103-1113.
18. Omloo JMT, Lagarde SM, Hulscher JBF, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarci- noma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992-1000.
19. Johansson J, DeMeester TR, Hagen JA, et al. En bloc vs. transhiatal esophagectomy for stage T3 N1 adenocarcinoma ofthe distal esophagus. Arch Surg. 2004;139:627-631; discussion 631-633.
20. Natsugoe S, Yoshinaka H, Shimada M, et al. Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann Surg. 2001;234:613-618.
21. Katsoulis IE, Wong WL, Mattheou AK, et al. Fluorine-18 fluorodeoxy- glucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Int J Surg. 2007;5:399-403.
22. Yuan S, Yu Y, Chao KSC, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nuclear Med. 2006;47:1255-1259.
23. Nishimura H, Tanigawa N, Hiramatsu M, et al. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with feru- moxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg. 2006;202:604 -611.
24. Henry LR, Goldberg M, Scott W, et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol. 2006;13:214-220.
25. Wright CD, Wain JC, Lynch TJ, et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg. 1997;114:811-815.
26. Liedman B, Johnsson E, Merke C, et al. Preoperative adjuvant radio- chemotherapy may increase the risk in patients undergoing thoracoab- dominal esophageal resections. Dig Surg. 2001;18:169 -175.